Sandoz Articles
NEW YORK STOCK COMMENT
25 March 1996
EUROPE STOCK COMMENT
25 March 1996
Drug Firms, HMOs And The Battle To Set US Prices
25 March 1996
W-Lambert And Schering-Plough Merger Targets?
25 March 1996
Hoechst Heads Into An Uncertain Future
25 March 1996
First NDA Approval Looms For Athena With Zanaflex
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Europe Stock Comment
18 March 1996
New York Stock Comment
18 March 1996
Independent Position To Be Maintained At Zeneca
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Mergermania In Euro Drug Industry: Will It Continue?
18 March 1996
Novartis Muscles In As Sandoz And Ciba Merge
11 March 1996
European Alzheimer's/ Dementia markets
11 March 1996
Sandoz To License Orion Parkinson's Drug
4 March 1996
European Deal For Canada's Allelix?
4 March 1996
Sweden's Pharma Market Expanded 12.7% In 1995
4 March 1996
EMEA Approves Roche's CellCept
26 February 1996
Losec "Will Be The World's Top-Selling Drug In 2000"
26 February 1996
SangStat Transplant Drug Shows Promise In Phase II
26 February 1996
Mycophenolate Approval in Europe Imminent, Says Roche
19 February 1996
SangStat's Ciclosporin "Bioequivalent"
19 February 1996
Thai PPA Directors
5 February 1996
Sandoz Licenses Human Skin Product
5 February 1996
EUROPEAN STOCK COMMENT
5 February 1996
EUROPEAN STOCK COMMENT
29 January 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
Somerset Pharma / Cocensys deal for Eldepryl
29 January 1996
Sandoz stops drug production in Greece
29 January 1996
Majors To Pay "Initial" $600 Mill To US Pharmacies
29 January 1996
London & Thames Valley Pharma Group appointment
22 January 1996
European Stock Comment
22 January 1996
Sales Growth For Sandoz In 1995
22 January 1996
Synthelabo's And Sandoz' Ratings Cut
22 January 1996
European Stock Markets Review 1995
22 January 1996
P&U Files In USA For Parkinson's Drug
15 January 1996
Management appointments at Sandoz
8 January 1996
Major M&As in 1995 As UK Industry Consolidates
8 January 1996
Phase III Data With Lilly's Olanzapine
8 January 1996
European Stock Comment
18 December 1995
Sandoz Launches Nasal Calcitonin In USA
18 December 1995
Sandoz sets up Hungarian subsidiary
4 December 1995
European Stock Comment
4 December 1995
Drug Trade Development In the Nordic Countries
27 November 1995
European Stock Comment
27 November 1995
French Drug Bourse Values Survive Juppe Reform Plan
27 November 1995
Novel Drugs Will Drive Euro Anti-Parkinson's Market
27 November 1995
Cortecs' Oral Calcitonin Closer To Market
20 November 1995
US FTC "Must Monitor Company/PBM Deals"
20 November 1995
SangStat ciclosporin trials
13 November 1995
Sandoz MDR Drug Shows Promise In Early Trials
13 November 1995
European stock comment
6 November 1995
Sandoz 9 Months Sales up 6%
6 November 1995
EUROPEAN STOCK COMMENT
23 October 1995
Strong Biotech Financing In 3rd Qtr
16 October 1995
Zeneca's Phase III Data Support Seroquel Efficacy
16 October 1995
European Stock Comment
16 October 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
BioTransplant Claims Two-Year Mismatched Transplant Survival
16 October 1995
Sandoz/Pharmacopeia alliance
9 October 1995
NDMA: Switching, labels, Alternative Therapies
2 October 1995
EUROPEAN STOCK COMMENT
18 September 1995
Watson Laboratories gets approval for Fiorinal
11 September 1995
Octreotide for AIDS-Related Diarrhea
11 September 1995
EUROPEAN STOCK COMMENT
11 September 1995
Sandoz' Calcitonin Spray Approved
11 September 1995
Reversal Of Bronchodilator Domination By 2000
4 September 1995
Drug Sales Boost Sandoz In First Half 1995
4 September 1995
European Stock Comment
4 September 1995
JAMA Study Ups Debate Over Calcium Blockers
4 September 1995
Procept's Anti-HIV Drug In Phase I/II
4 September 1995
US OK For Miacalcin
4 September 1995
Sandoz' Neoral Free To South African Children
14 August 1995
Forthcoming Industry Meetings
7 August 1995
Sandoz's Neoral approved in the USA
31 July 1995
European Drug Sector Still Undervalued, Says Broker
31 July 1995
Sandoz Half-Year Sales Up 6%, But Pharma Down 2%
24 July 1995
NEW YORK STOCK COMMENT
17 July 1995
EUROPEAN STOCK COMMENT
17 July 1995
US Sales of Generic Drugs Up 29% In 1994, Says IMS
17 July 1995
Sandoz Acquires Genetic Therapy For $295 Million
17 July 1995
Management changes at Sandoz
10 July 1995
European stock comment
10 July 1995
GTI Starts Further Brain Tumor Trial
10 July 1995
CellCept Launched In 1st Market
3 July 1995
World Pharma Firm League, According To PMSI
3 July 1995
Sandoz sets share price for Clariant
26 June 1995
France's Ethypharm Targets China Mart
26 June 1995
Bayer's First Pipeline Presentation: Part 1
19 June 1995
Sandoz floats Clariant
12 June 1995
Sandoz's Parloel and Zaditen in France
12 June 1995
Ciba-Affymax Research Deal To End
12 June 1995
OTC Firms Agree Dispute Procedure
29 May 1995
The ABPI's A-Z Of British Medicines Research
29 May 1995
Richard appointed senior VP at Sandoz
22 May 1995
GTI Gains Patent Rights To Brain Tumor Tech
22 May 1995
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
